Your specialty Our products Why Biocomposites? Education Library News & Events Contact us Home News Biocomposites announces new CE Mark for STIMULAN® International News 23 Apr 20 Biocomposites announces new CE Mark for STIMULAN® First calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue Keele, UK, 23 April 2020 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announced that its STIMULAN products have gained a new European CE mark approval for mixing with antibiotics: vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue. STIMULAN® targets high concentrations of antibiotic at the point of infection at levels unachievable systemically – which lowers rates of reinfection, saves costs and improves patient outcomes. The STIMULAN® Rapid Cure and STIMULAN® Kit products are the first and only calcium matrices that can carry an antibiotic into bone and soft tissue; offering surgeons the flexibility to apply a broad spectrum of ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans. Mr Rhidian Morgan-Jones, Consultant Orthopaedic Surgeon, said: “STIMULAN® is the only product that allows me to place the appropriate antibiotics in bone and soft tissue when treating very challenging infected cases. It has played a key role in transforming the outcomes of some very difficult cases.” Michael Harris, Chief Executive Officer of Biocomposites, said: “Our goal is to develop and provide products that can significantly improve patient outcomes and decrease hospital readmissions. This is a breakthrough solution for surgeons managing infection, offering them the flexibility to use their chosen antibiotics at patient-specific concentration levels in both bone and soft tissue.” STIMULAN® is already used in over 50,000 cases every year and in thousands of hospitals around the world. Contact for Media enquiries Optimum Strategic Communications Hollie Vile, Stella Lempidaki, Zoe Bolt Tel: +44 (0)20 3950 9144 biocomposites@optimumcomms.com About Biocomposites Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more. Other news Listed below is a list of the 4 most recent news updates made by Biocomposties Visit our News & Events page News 28 Sep 21 Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting Keele, UK, 28 September 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world…... View News Article > News 31 Aug 21 Biocomposites to present data on STIMULAN® and genex® at American Academy of Orthopaedic Surgeons Annual Meeting Keele, UK, 31 August 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world…... View News Article > News 4 Aug 21 Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021 Keele, UK, 4 August 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world…... View News Article > News 7 Jul 21 Biocomposites announces new approval for STIMULAN® to treat bacterial infection Keele, UK, 7 July 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading…... View News Article > Library Interested in other types of our content? See a list of some of our most recent below. Explore Library genex® Effectiveness of the management of bony articular collapse with bony defects in tibial plateau fractures with the use of genex: An absorbable calcium composite synthetic bone graft Lowery, K., et al. Journal of Limb Lengthening & Reconstruction 2018, 4(1): 20-25. View paper > genex® Arthroscopically assisted use of injectable bone graft substitutes for management of scaphoid nonunions Chu, P. J. and J. T. Shih. Arthroscopy 2011, 27(1): 31-37. View paper > genex® Use of genex in the treatment of a tibial plateau fracture View case study > STIMULAN® Transform infected THR View case study > Your specialty Musculoskeletal infection Trauma Spine Sports injuries Our products STIMULAN® genex® Biosteon® Allogran-R® Bilok® Why Biocomposites? News & Events Contact us Education Biofilm Infected fractures Periprosthetic joint infection (PJI) Wound closure Our company COVID19 risk assessment Legal notices Sitemap Privacy statement Code of conduct Modern slavery statement Section 172 statement LinkedIn Twitter ©2021, Biocomposites. All rights reserved.